Suncoast Equity Management Has $42.81 Million Stock Position in Stryker Corporation $SYK

by · The Markets Daily

Suncoast Equity Management decreased its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 121,793 shares of the medical technology company’s stock after selling 2,035 shares during the period. Stryker makes up approximately 4.3% of Suncoast Equity Management’s investment portfolio, making the stock its 10th biggest position. Suncoast Equity Management’s holdings in Stryker were worth $42,807,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $27,000. CGC Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $29,000. Strive Asset Management LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Stryker during the 3rd quarter valued at about $34,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is currently owned by company insiders.

Stryker Price Performance

Shares of Stryker stock opened at $305.73 on Monday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The stock’s fifty day moving average is $321.82 and its 200 day moving average is $348.10. The stock has a market cap of $117.21 billion, a P/E ratio of 35.39, a P/E/G ratio of 1.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SYK. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Canaccord Genuity Group cut their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Finally, BTIG Research cut their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Check Out Our Latest Stock Report on Stryker

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).